These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 20556817)

  • 41. Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: a double-blind trial.
    Yocum DE; Furst DE; Kaine JL; Baldassare AR; Stevenson JT; Borton MA; Mengle-Gaw LJ; Schwartz BD; Wisemandle W; Mekki QA;
    Arthritis Rheum; 2003 Dec; 48(12):3328-37. PubMed ID: 14673984
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study.
    Bruyn GA; Tate G; Caeiro F; Maldonado-Cocco J; Westhovens R; Tannenbaum H; Bell M; Forre O; Bjorneboe O; Tak PP; Abeywickrama KH; Bernhardt P; van Riel PL;
    Ann Rheum Dis; 2008 Aug; 67(8):1090-5. PubMed ID: 18037627
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis: a randomized, double blind, placebo controlled dose-finding study.
    Kondo H; Abe T; Hashimoto H; Uchida S; Irimajiri S; Hara M; Sugawara S
    J Rheumatol; 2004 Feb; 31(2):243-51. PubMed ID: 14760792
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group.
    Strand V; Tugwell P; Bombardier C; Maetzel A; Crawford B; Dorrier C; Thompson A; Wells G
    Arthritis Rheum; 1999 Sep; 42(9):1870-8. PubMed ID: 10513801
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.
    Kavanaugh A; St Clair EW; McCune WJ; Braakman T; Lipsky P
    J Rheumatol; 2000 Apr; 27(4):841-50. PubMed ID: 10782805
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis.
    Keystone E; Fleischmann R; Emery P; Furst DE; van Vollenhoven R; Bathon J; Dougados M; Baldassare A; Ferraccioli G; Chubick A; Udell J; Cravets MW; Agarwal S; Cooper S; Magrini F
    Arthritis Rheum; 2007 Dec; 56(12):3896-908. PubMed ID: 18050221
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine.
    Keystone EC; Wang MM; Layton M; Hollis S; McInnes IB;
    Ann Rheum Dis; 2012 Oct; 71(10):1630-5. PubMed ID: 22966146
    [TBL] [Abstract][Full Text] [Related]  

  • 48. VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis.
    Genovese MC; van Vollenhoven RF; Pacheco-Tena C; Zhang Y; Kinnman N
    Arthritis Rheumatol; 2016 Jan; 68(1):46-55. PubMed ID: 26473751
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies.
    Damjanov N; Kauffman RS; Spencer-Green GT
    Arthritis Rheum; 2009 May; 60(5):1232-41. PubMed ID: 19404957
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo.
    Kremer JM; Bloom BJ; Breedveld FC; Coombs JH; Fletcher MP; Gruben D; Krishnaswami S; Burgos-Vargas R; Wilkinson B; Zerbini CA; Zwillich SH
    Arthritis Rheum; 2009 Jul; 60(7):1895-905. PubMed ID: 19565475
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial.
    Weinblatt ME; Kavanaugh A; Burgos-Vargas R; Dikranian AH; Medrano-Ramirez G; Morales-Torres JL; Murphy FT; Musser TK; Straniero N; Vicente-Gonzales AV; Grossbard E
    Arthritis Rheum; 2008 Nov; 58(11):3309-18. PubMed ID: 18975322
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Organ messenger ribonucleic acid and plasma proteome changes in the adjuvant-induced arthritis model: responses to disease induction and therapy with the estrogen receptor-beta selective agonist ERB-041.
    Follettie MT; Pinard M; Keith JC; Wang L; Chelsky D; Hayward C; Kearney P; Thibault P; Paramithiotis E; Dorner AJ; Harris HA
    Endocrinology; 2006 Feb; 147(2):714-23. PubMed ID: 16269464
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis.
    Bradley JD; Dmitrienko AA; Kivitz AJ; Gluck OS; Weaver AL; Wiesenhutter C; Myers SL; Sides GD
    J Rheumatol; 2005 Mar; 32(3):417-23. PubMed ID: 15742431
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chinese herbal medicine Xinfeng Capsule in treatment of rheumatoid arthritis: study protocol of a multicenter randomized controlled trial.
    Liu J; Huang CB; Wang Y; Xu GQ; Cheng YY; Feng YX; Liu L; Qi YJ
    J Integr Med; 2013 Nov; 11(6):428-34. PubMed ID: 24299607
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Novel Highly Bioavailable Curcumin Formulation Improves Symptoms and Diagnostic Indicators in Rheumatoid Arthritis Patients: A Randomized, Double-Blind, Placebo-Controlled, Two-Dose, Three-Arm, and Parallel-Group Study.
    Amalraj A; Varma K; Jacob J; Divya C; Kunnumakkara AB; Stohs SJ; Gopi S
    J Med Food; 2017 Oct; 20(10):1022-1030. PubMed ID: 28850308
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of rheumatoid arthritis with ornidazole: a randomized, double-blind, placebo-controlled study.
    Ogrendik M
    Rheumatol Int; 2006 Oct; 26(12):1132-7. PubMed ID: 16770616
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Results of a proof of concept, double-blind, randomized trial of a second generation antisense oligonucleotide targeting high-sensitivity C-reactive protein (hs-CRP) in rheumatoid arthritis.
    Warren MS; Hughes SG; Singleton W; Yamashita M; Genovese MC
    Arthritis Res Ther; 2015 Mar; 17(1):80. PubMed ID: 25885521
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of tacrolimus and mizoribine in a randomized, double-blind controlled study in patients with rheumatoid arthritis.
    Kawai S; Hashimoto H; Kondo H; Murayama T; Kiuchi T; Abe T
    J Rheumatol; 2006 Nov; 33(11):2153-61. PubMed ID: 16960930
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An estrogen receptor-beta agonist is active in models of inflammatory and chemical-induced pain.
    Leventhal L; Brandt MR; Cummons TA; Piesla MJ; Rogers KE; Harris HA
    Eur J Pharmacol; 2006 Dec; 553(1-3):146-8. PubMed ID: 17056036
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of an estrogen receptor-beta agonist in animal models of human disease.
    Harris HA; Albert LM; Leathurby Y; Malamas MS; Mewshaw RE; Miller CP; Kharode YP; Marzolf J; Komm BS; Winneker RC; Frail DE; Henderson RA; Zhu Y; Keith JC
    Endocrinology; 2003 Oct; 144(10):4241-9. PubMed ID: 14500559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.